MML Investors Services LLC Acquires Shares of 684 United Therapeutics Co. (NASDAQ:UTHR)

MML Investors Services LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 684 shares of the biotechnology company’s stock, valued at approximately $245,000.

Several other institutional investors have also modified their holdings of the business. ClariVest Asset Management LLC raised its holdings in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. Innealta Capital LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth about $33,000. USA Financial Formulas acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at about $33,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics during the third quarter worth about $33,000. Finally, Capital Performance Advisors LLP acquired a new position in United Therapeutics in the third quarter worth about $82,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In other news, Director Christopher Causey sold 510 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares in the company, valued at $1,384,115.25. This represents a 12.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 137,753 shares of company stock worth $51,787,157 over the last three months. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $360.87 on Thursday. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The business’s fifty day moving average price is $371.01 and its two-hundred day moving average price is $347.25. The company has a market capitalization of $16.11 billion, a P/E ratio of 15.85, a PEG ratio of 1.05 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.38 earnings per share. On average, research analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on UTHR shares. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. LADENBURG THALM/SH SH lifted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group boosted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. HC Wainwright raised their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, Argus increased their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.